Suppr超能文献

N-甲基异靛红-β-硫代半卡巴腙衍生物(SCH 16)在体外和体内均是日本脑炎病毒感染的抑制剂。

N-methylisatin-beta-thiosemicarbazone derivative (SCH 16) is an inhibitor of Japanese encephalitis virus infection in vitro and in vivo.

作者信息

Sebastian Liba, Desai Anita, Shampur Madhusudana N, Perumal Yogeeswari, Sriram D, Vasanthapuram Ravi

机构信息

Department of Neurovirology, National Institute of Mental Health and Neuro Sciences, Bangalore-560029, India.

出版信息

Virol J. 2008 May 22;5:64. doi: 10.1186/1743-422X-5-64.

Abstract

BACKGROUND

During the early and mid part of 20th century, several reports described the therapeutic effects of N-methylisatin-beta-Thiosemicarbazone (MIBT) against pox viruses, Maloney leukemia viruses and recently against HIV. However, their ability to inhibit flavivirus replication has not been investigated. Hence the present study was designed to evaluate the antiviral activity of 14 MIBT derivatives against Flaviviruses that are prevalent in India such as Japanese Encephalitis Virus (JEV), Dengue-2 (Den-2) and West Nile viruses (WNV).

RESULTS

Amongst the fourteen Mannich bases of MIBT derivatives tested one compound - SCH 16 was able to completely inhibit in vitro Japanese encephalitis virus (JEV) and West Nile virus (WNV) replication. However no antiviral activity of SCH 16 was noted against Den-2 virus replication. This compound was able to inhibit 50% of the plaques (IC50) produced by JEV and WNV at a concentration of 16 microgm/ml (0.000025 microM) and 4 microgm/ml (0.000006 microM) respectively. Furthermore, SCH 16 at a concentration of 500 mg/kg body weight administered by oral route twice daily was able to completely (100%) prevent mortality in mice challenged with 50LD50 JEV by the peripheral route. Our experiments to understand the mechanism of action suggest that SCH 16 inhibited JEV replication at the level of early protein translation.

CONCLUSION

Only one of the 14 isatin derivatives -SCH 16 exhibited antiviral action on JEV and WNV virus infection in vitro. SCH 16 was also found to completely inhibit JEV replication in vivo in a mouse model challenged peripherally with 50LD50 of the virus. These results warrant further research and development on SCH 16 as a possible therapeutic agent.

摘要

背景

在20世纪早期和中期,有几份报告描述了N-甲基异靛-β-硫代半卡巴腙(MIBT)对痘病毒、莫洛尼白血病病毒以及最近对HIV的治疗效果。然而,其抑制黄病毒复制的能力尚未得到研究。因此,本研究旨在评估14种MIBT衍生物对印度流行的黄病毒,如日本脑炎病毒(JEV)、登革热2型病毒(Den-2)和西尼罗河病毒(WNV)的抗病毒活性。

结果

在所测试的14种MIBT衍生物的曼尼希碱中,一种化合物——SCH 16能够完全抑制体外日本脑炎病毒(JEV)和西尼罗河病毒(WNV)的复制。然而,未观察到SCH 16对Den-2病毒复制有抗病毒活性。该化合物能够分别在浓度为16微克/毫升(0.000025微摩尔)和4微克/毫升(0.000006微摩尔)时抑制JEV和WNV产生的50%的噬斑(IC50)。此外,每天口服两次、浓度为500毫克/千克体重的SCH 16能够完全(100%)预防经外周途径感染50LD50 JEV的小鼠死亡。我们旨在了解作用机制的实验表明,SCH 16在早期蛋白质翻译水平抑制JEV复制。

结论

14种异靛衍生物中只有一种——SCH 16在体外对JEV和WNV病毒感染表现出抗病毒作用。还发现SCH 16在经外周途径用50LD50病毒攻击的小鼠模型中能够完全抑制体内JEV复制。这些结果为将SCH 16作为一种可能的治疗药物进行进一步研究和开发提供了依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8097/2408923/ff07ff937560/1743-422X-5-64-1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验